Changeflow GovPing Healthcare & Life Sciences Phase 3 Dimethyl Fumarate Trial, Type 1 Diabete...
Routine Notice Added Final

Phase 3 Dimethyl Fumarate Trial, Type 1 Diabetes, Adults

Email

Summary

A Phase 3 clinical trial for Dimethyl Fumarate in adults with Type 1 Diabetes has been registered in ClinicalTrials.gov under identifier NCT07548996. The trial is categorized under Phase 3 and appears in the registry sorted by start date. This registration documents the existence and parameters of an interventional study without providing additional trial design details, enrollment numbers, or recruitment status in this entry.

Published by NIH on clinicaltrials.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors ClinicalTrials.gov - Phase 3 Trials by Start Date for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 3 changes logged to date.

What changed

This entry records the registration of a Phase 3 clinical trial for Dimethyl Fumarate as a treatment for Type 1 Diabetes in adult participants. ClinicalTrials.gov serves as the public registry, and this listing provides the trial identifier (NCT07548996) and phase classification. No compliance obligations, reporting requirements, or regulatory deadlines are established by this registration entry.

Pharmaceutical companies, clinical investigators, and institutional review boards monitoring the clinical trial landscape may use this registry entry to identify active Phase 3 studies in the Type 1 Diabetes therapeutic area. Sponsors conducting competitive intelligence or patient recruitment for related studies should note this trial's registration status.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Show glossary

Get daily alerts for ClinicalTrials.gov - Phase 3 Trials by Start Date

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Clinical investigators
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Clinical trial registration Drug research
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Regulatory Affairs
Topics
Healthcare Medical Devices

Get alerts for this source

We'll email you when ClinicalTrials.gov - Phase 3 Trials by Start Date publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!